Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.

Viani, Rolando M; Ruel, Theodore; Alvero, Carmelita; Fenton, Terry; Acosta, Edward P; Hazra, Rohan; Townley, Ellen; Palumbo, Paul; Buchanan, Ann M; Vavro, Cindy; Singh, Rajendra; Graham, Bobbie; Anthony, Patricia; George, Kathleen; Wiznia, Andrew

Viani, Rolando M; Ruel, Theodore; Alvero, Carmelita; Fenton, Terry; Acosta, Edward P; Hazra, Rohan; Townley, Ellen; Palumbo, Paul; Buchanan, Ann M; Vavro, Cindy; Singh, Rajendra; Graham, Bobbie; Anthony, Patricia; George, Kathleen; Wiznia, Andrew.

Afiliação

Viani RM; Department of Pediatrics, University of California, San Diego and Rady Children's Hospital San Diego, La Jolla.
Ruel T; Division of Pediatric Infectious Diseases and Global Health, Department of Pediatrics, University of California, San Francisco.
Alvero C; Statistical and Data Analysis Center, Harvard School Public Health, Boston, Massachusetts.
Fenton T; Statistical and Data Analysis Center, Harvard School Public Health, Boston, Massachusetts.
Acosta EP; University of Alabama at Birmingham.
Hazra R; Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Townley E; Columbus Technologies and Services, Contractor to the Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Palumbo P; Division of Infectious Diseases, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Buchanan AM; ViiV Healthcare, Research Triangle Park, North Carolina.
Vavro C; ViiV Healthcare, Research Triangle Park, North Carolina.
Singh R; ViiV Healthcare, Research Triangle Park, North Carolina.
Graham B; Frontier Science Inc, Buffalo, New York.
Anthony P; University of Southern California, Los Angeles.
George K; FHI 360, Durham, North Carolina.
Wiznia A; Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York.

J Pediatric Infect Dis Soc ; 9(2): 159-165, 2020 Apr 30.

Article em En | MEDLINE | ID: mdl-30951600

Assuntos

Farmacorresistência Viral/genética; Infecções por HIV/tratamento farmacológico; Inibidores de Integrase de HIV/uso terapêutico; HIV-1; Compostos Heterocíclicos com 3 Anéis/uso terapêutico; Mutação; Oxazinas/uso terapêutico; Piperazinas/uso terapêutico; Piridonas/uso terapêutico; Adolescente; Antirretrovirais/uso terapêutico; Criança; Quimioterapia Combinada; Feminino; Infecções por HIV/virologia; Inibidores de Integrase de HIV/efeitos adversos; HIV-1/genética; HIV-1/isolamento & purificação; Compostos Heterocíclicos com 3 Anéis/efeitos adversos; Humanos; Masculino; Adesão à Medicação; Oxazinas/efeitos adversos; Piperazinas/efeitos adversos; Piridonas/efeitos adversos; RNA Viral/sangue; Resultado do Tratamento; Carga Viral

Palavras-chave

Adolescent; Antiretroviral agents; Dolutegravir; HIV-1 integrase inhibitors; long-term follow-up

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazinas / Piperazinas / Piridonas / Infecções por HIV / HIV-1 / Inibidores de Integrase de HIV / Farmacorresistência Viral / Compostos Heterocíclicos com 3 Anéis / Mutação Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Pediatric Infect Dis Soc Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google